Literature DB >> 19526464

How druggable is protein kinase CK2?

Giorgio Cozza1, Andrea Bortolato, Stefano Moro.   

Abstract

CK2 is a pleiotropic, ubiquitous, and constitutively active protein kinase (PK), with both cytosolic and nuclear localization in most mammalian cells. The holoenzyme is generally composed of two catalytic (alpha and/or alpha') and two regulatory (beta) subunits, but the free alpha/alpha' subunits are catalytically active by themselves and can be present in cells under some circumstances. CK2 catalyzes the phosphorylation of more than 300 substrates characterized by multiple acidic residues surrounding the phosphor-acceptor amino acid, and, consequently, it plays a key role in several physiological and pathological processes. But how can one kinase orchestrate all these tasks faithfully? How is it possible that one kinase can, despite all pleiotropic characteristics of PKs in general, be involved in so many different biochemical events? Is CK2 a druggable target? Several questions are still to be clearly answered, and this review is an occasion for a fruitful discussion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19526464     DOI: 10.1002/med.20164

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  18 in total

1.  Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.

Authors:  Fabrice Pierre; Peter C Chua; Sean E O'Brien; Adam Siddiqui-Jain; Pauline Bourbon; Mustapha Haddach; Jerome Michaux; Johnny Nagasawa; Michael K Schwaebe; Eric Stefan; Anne Vialettes; Jeffrey P Whitten; Ta Kung Chen; Levan Darjania; Ryan Stansfield; Joshua Bliesath; Denis Drygin; Caroline Ho; May Omori; Chris Proffitt; Nicole Streiner; William G Rice; David M Ryckman; Kenna Anderes
Journal:  Mol Cell Biochem       Date:  2011-07-14       Impact factor: 3.396

2.  Identification of novel CK2 inhibitors with a benzofuran scaffold by novel non-radiometric in vitro assays.

Authors:  Andreas Gratz; Uwe Kuckländer; Ricardo Bollig; Claudia Götz; Joachim Jose
Journal:  Mol Cell Biochem       Date:  2011-07-13       Impact factor: 3.396

3.  Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2.

Authors:  Andriy G Golub; Volodymyr G Bdzhola; Yaroslav V Kyshenia; Vladislav M Sapelkin; Andriy O Prykhod'ko; Olexander P Kukharenko; Olga V Ostrynska; Sergiy M Yarmoluk
Journal:  Mol Cell Biochem       Date:  2011-07-07       Impact factor: 3.396

4.  Coupling Supervised Molecular Dynamics (SuMD) with Entropy Estimations To Shine Light on the Stability of Multiple Binding Sites.

Authors:  Shailesh Kumar Panday; Mattia Sturlese; Veronica Salmaso; Indira Ghosh; Stefano Moro
Journal:  ACS Med Chem Lett       Date:  2019-02-15       Impact factor: 4.345

5.  Casein kinase 2 (CK2) phosphorylates the deubiquitylase OTUB1 at Ser16 to trigger its nuclear localization.

Authors:  Lina Herhaus; Ana B Perez-Oliva; Giorgio Cozza; Robert Gourlay; Simone Weidlich; David G Campbell; Lorenzo A Pinna; Gopal P Sapkota
Journal:  Sci Signal       Date:  2015-04-14       Impact factor: 8.192

6.  Antitumoral activity of allosteric inhibitors of protein kinase CK2.

Authors:  Virginie Moucadel; Renaud Prudent; Céline F Sautel; Florence Teillet; Caroline Barette; Laurence Lafanechere; Veronique Receveur-Brechot; Claude Cochet
Journal:  Oncotarget       Date:  2011-12

7.  Inhibition of CK2α down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells.

Authors:  Shulin Zhang; Yucheng Wang; Jian-Hua Mao; David Hsieh; Il-Jin Kim; Li-Min Hu; Zhidong Xu; Hao Long; David M Jablons; Liang You
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

8.  Phospholipases and the Network of Auxin Signal Transduction with ABP1 and TIR1 as Two Receptors: A Comprehensive and Provocative Model.

Authors:  Günther F E Scherer; Corinna Labusch; Yunus Effendi
Journal:  Front Plant Sci       Date:  2012-04-09       Impact factor: 5.753

9.  CK2α, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells.

Authors:  Shulin Zhang; Yi-Lin Yang; Yucheng Wang; Bin You; Yuyuan Dai; Geraldine Chan; David Hsieh; Il-Jin Kim; Li Tai Fang; Alfred Au; Hubert J Stoppler; Zhidong Xu; David M Jablons; Liang You
Journal:  J Exp Clin Cancer Res       Date:  2014-11-25

10.  Insights into the Impact of Linker Flexibility and Fragment Ionization on the Design of CK2 Allosteric Inhibitors: Comparative Molecular Dynamics Simulation Studies.

Authors:  Yue Zhou; Na Zhang; Xiaoqian Qi; Shan Tang; Guohui Sun; Lijiao Zhao; Rugang Zhong; Yongzhen Peng
Journal:  Int J Mol Sci       Date:  2018-01-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.